日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial

吉西他滨辅助治疗与新辅助/辅助 FOLFIRINOX 方案治疗可切除胰腺癌的疗效比较:随机多中心 II 期 NEPAFOX 试验

Goetze, Thorsten O; Reichart, Alexander; Bankstahl, Ulli S; Pauligk, Claudia; Loose, Maria; Kraus, Thomas W; Elshafei, Moustafa; Bechstein, Wolf O; Trojan, Jörg; Behrend, Matthias; Homann, Nils; Venerito, Marino; Bohle, Wolfram; Varvenne, Michael; Bolling, Claus; Behringer, Dirk M; Kratz-Albers, Karsten; Siegler, Gabriele M; Hozaeel, Wael; Al-Batran, Salah-Eddin

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO

预防性腹腔热灌注化疗联合围手术期FLOT治疗与单独使用FLOT治疗可切除的弥漫型胃癌和胃食管交界处II/III型腺癌的疗效比较——AIO/CAOGI/ACO开展的III期“预防”(FLOT9)试验

Götze, Thorsten O; Piso, Pompiliu; Lorenzen, Sylvie; Bankstahl, Ulli S; Pauligk, Claudia; Elshafei, Moustafa; Amato, Giuseppe; Reim, Daniel; Bechstein, Wolf O; Königsrainer, Alfred; Mönig, Stefan P; Rau, Beate; Schwarzbach, Matthias; Al-Batran, Salah-Eddin